![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rochester Medical Corp. (MM) | NASDAQ:ROCM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.00 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | March 11, 2008 |
Rochester Medical Corporation
__________________________________________
(Exact name of registrant as specified in its charter)
Minnesota | 0-18933 | 41-1613227 |
_____________________
(State or other jurisdiction |
_____________
(Commission |
______________
(I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
One Rochester Medical Drive, Stewartville, Minnesota | 55976 | |
_________________________________
(Address of principal executive offices) |
___________
(Zip Code) |
Registrants telephone number, including area code: | 507-533-9600 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Changes in Registrant's Certifying Accountant.
(a) On March 11, 2008, the Audit Committee of the Board of Directors of Rochester Medical Corporation (the "Company"), after a review of proposals for audit services from several public accountants, decided to engage Grant Thornton LLP as independent registered public accounting firm of the Company for the fiscal year commencing October 1, 2007 and ending September 30, 2008. McGladrey & Pullen LLP ("McGladrey & Pullen"), the current independent registered public accounting firm, was dismissed by the Audit Committee of the Board of Directors of the Company as of March 11, 2008.
In connection with the audits of the two fiscal years ended September 30, 2007, and the subsequent interim period through March 11, 2008, there were no disagreements between the Company and McGladrey & Pullen on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of McGladrey & Pullen, would have caused McGladrey & Pullen to make reference in connection with their opinion to the subject matter of the disagreement.
There were no reportable events (as defined in Regulation S-K Item 304(a)(1)(v)) during the two most recent fiscal years of the Company ended September 30, 2007, or the subsequent interim period through March 11, 2008.
The audit reports of McGladrey & Pullen on the Company’s consolidated financial statements as of and for the years ended September 30, 2007 and September 30, 2006 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
A letter from McGladrey & Pullen LLP is attached as Exhibit 16.1 to this Form 8-K.
(b) On March 13, 2008, the Audit Committee of the Company engaged Grant Thornton LLP as the Company's new independent registered public accounting firm. During the Company’s two most recent fiscal years and the subsequent interim period through February 29, 2008, the Company did not consult with Grant Thornton LLP regarding any of the matters set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
16.1 Letter from McGladrey & Pullen LLP to the Securities and Exchange Commission dated March 14, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Rochester Medical Corporation | ||||
March 14, 2008 | By: |
/s/ David A. Jonas
|
||
|
||||
Name: David A. Jonas | ||||
Title: Chief Financial Officer |
Exhibit Index
Exhibit No.
Description
Letter from McGladrey & Pullen LLP
1 Year Rochester Medical Corp. (MM) Chart |
1 Month Rochester Medical Corp. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions